Please login to the form below

Not currently logged in
Email:
Password:

Protein coat for nanowires could lower harmful medicine dosages

Scientists in Idaho and Korea reveal the development of a protein coating which could turn nanowires into a new drug delivery system, helping to target doses of medicines harmful to humans

Scientists in Idaho and Korea have revealed the development of a protein coating which could turn nanowires into a new drug delivery system, helping to target doses of medicines harmful to humans.

The study leaders at the University of Idaho, Gregory Bohach, David McIlroy and Carolyn Hovde, reported that nanowires and other nanomaterials (NM), which are 50,000 times smaller in diameter than a human hair, could be used penetrate tumours more easily.

The researchers reported that nanowires coated with the protein fibronectin penetrated cells more easily than uncoated nanowires. They added that the wires could also be coated with antibodies or other materials which home in on abnormal cells, while sparing normal cells.

In experiments with human and bovine cells, results showed that coated nanowires could enter and deliver a toxic agent called StxA1 which then killed the cells.

Professor Bohach said: "This indicates that nanowires can carry StxA1 and potentially other toxic or therapeutic agents into cells."

4th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics